VANCOUVER, BC and BEL-AIR, CA / ACCESSWIRE / May 30, 2019 / Burcon NutraScience Corporation (TSX: BU), a global leader in developing functionally and nutritionally valuable plant-proteins, has been invited to present at the 9th Annual LD Micro Invitational Conference being held on June 4-5, 2019 at the Luxe Sunset Hotel in Bel-Air, California.

Burcon CEO, Johann Tergesen, is scheduled to present on June 4, 2019 at 9:00 a.m. PT with one-on-one meetings throughout the day. He will be discussing Burcon’s recently announced plans to build a US$48.4 million protein production facility that will be co-funded by a key investor group. The plant will produce unique, highly purified pea and canola protein ingredients based on Burcon’s patented technologies.

The launch of the production facility comes at a time when companies like Beyond Meat and Impossible Foods are raising large sums in order to expand their operations and keep up with demand. According to industry researchers, the global plant-based protein ingredients market is growing at compounded annual rate of 5.7% and is expected to reach US$16.3 billion by 2025.

The event is one of the nation’s largest independent conferences for small/micro-cap companies, with more than 250 names presenting to more than 1,000 attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest to investors and issuers.

To schedule a one-on-one meeting with Burcon, you may submit your request online via the link provided upon registration. To register for the conference, contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events.

For questions about the company, contact Paul Lam at (604) 733-0896 or email plam@burcon.ca.

View Burcon’s profile here: https://www.ldmicro.com/profile/BU.TO

Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually. In 2015, LD Micro launched the first pure microcap index to exclusively provide intraday information on the entire sector. LD provides tools for the benefit of everyone in the small and microcap universe. To register and attend the event, please visit www.ldmicro.com/events.

About Burcon NutraScience Corporation

Burcon is a leader in developing functionally and nutritionally valuable plant proteins. The company has developed an extensive portfolio of composition, application, and process patents originating from a core protein extraction and purification technology.

Burcon’s CLARISOY® soy protein – under license to the Archer Daniels Midland Company – offers clarity and high-quality protein nutrition for low-pH beverage systems, and excellent solubility and exceptionally clean flavour at any pH; Peazazz® is a uniquely soluble and clean-tasting pea protein; and Puratein®, Supertein® and Nutratein® are canola protein isolates with exceptional functionality and valuable nutritional profiles. For more information about the company, visit www.burcon.ca.

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “project,” “estimate,” “expect,” “believe”, “future,” “likely,” “may,” “should,” “could”, “will” and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon’s plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled “Risk Factors” in Burcon’s annual information form dated June 18, 2018 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.

CLARISOY is a trademark of Archer Daniels Midland Company.

Investor Contact:

Paul Lam
Manager, Business Development
Burcon NutraScience Corporation
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca www.burcon.ca

Media Contact:

Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM

SOURCE: Burcon NutraScience Corporation

ReleaseID: 547078

CALGARY, AB / ACCESSWIRE / May 30, 2019 / Point Loma Resources Ltd. (TSX VENTURE: PLX) (the “Corporation” or “Point Loma”) is pleased to announce a farm-out on the Corporation’s evolving Wizard Lake Rex oil discovery and provides an operational update.

Highlights:

Point Loma’s current 30% working interest partner, Salt Bush Energy Ltd. (“Salt Bush”), has agreed to a two well farm-in transaction with Point Loma at Wizard Lake whereby Salt Bush will incur 100% of the costs to drill, complete and equip up to two wells.
The current plan for the two earning wells would be to drill from existing pad locations to reduce time and cost to bring the wells on stream.
A test well and an option well are planned on Point Loma’s Wizard Lake property as follow-up to the successful Rex oil discovery well 16-17-48-27W4M HZ drilled in Q4-2018.
Both the test well and option well will be horizontally drilled with respective targeted lateral minimum lengths of 1400 meters and 1800 meters and will utilize multi-stage frac completions.
The test well is to spud by August 15, 2019 and Point Loma will retain a 25% working interest before payout (“BPO”) and 60% after payout (“APO”).
The option well, upon Salt Bush’s election to proceed, is to be drilled by December 31, 2019 and Point Loma will retain a 25% working interest BPO and 50% APO.
Once earning is complete in both wells, Point Loma and Salt Bush will be 50/50 working interest partners in the Wizard Lake Rex oil development and Point Loma will retain operatorship.
The Wizard Lake discovery well 16-17-48-27W4 HZ is expected to commence production in early June 2019 upon completion of facilities construction.

Wizard Lake Rex Oil (70% WI) – Commencing First Oil Production Early June and Horizontal Drilling Update

A successful fully completed 2 well farm-out would result in three producing oil wells. Point Loma would be the operator with a 50% working interest in the Rex oil discovery well, a 25% BPO / 50% APO working interest in both the test well and the earning well and a 50% working interest in the remaining lands. A total of approximately $5 million of gross capital would be spent on the two well farm-out to delineate the pool at no cost to Point Loma.

Point Loma commenced construction of production facilities at its recently drilled and tested Rex oil discovery well in Q2-2019. Production is currently expected to commence in early June 2019. As disclosed in the press release of January 21, 2019 the 16-17-48-27W4 well tested at rates in excess of 300 bpd of oil with increasing oil cuts through the end of the testing period which has led to substantial reserve bookings for the pool net to Point Loma. Also of note, after the flow test, actual oil sales were 55% above field measured amounts (actual oil sales of 2,849 bbls vs field measurements of 1,847 bbls).

In addition to proved plus probable non-producing reserves of 150 mbbl (105 mbbl working interest) the Corporation received three additional proven undeveloped and one additional probable locations booked to the pool. In total the net proven and probable reserves booked were 525 mbbl of oil with a net present value discounted at 10% of $8.8 million.

This property represents a key oil discovery for Point Loma and could increase the oil production weighting for the Corporation significantly. At tested rates this would represent a corporate shift of oil and ngl product weighting from approximately 30% to approximately 40-45% of the Corporation’s total net production. Follow-up drilling could further move the production split to an even higher oil weighting.

The farm-out with Salt Bush will delineate the pool with a 1400m horizontal and a 1800m horizontal wells to be completed with multi-stage fracs. This is expected to assist in confirmation of pool size and also oil productivity and will test the application of extended reach wells for further development of the pool. With success on the two farm-out wells Point Loma will not only receive additional revenues but should be able to demonstrate the economics of full field development.

Upper Mannville Oil (PLX 80% Working Interest) – Expansion Opportunity to the North of Existing Oil Development

Point Loma has internally identified and captured a Mannville pool target north of the Corporation’s Paddle River Lower Mannville oil producing property. The target is analogous to the Rex oil discovery at Wizard lake that is operated by Point Loma. This could result in 15-20 follow-up opportunities with success. This opportunity has pipeline connection to a deep cut gas facility in the area which could accelerate on-stream timing and future development.

Lower Mannville Oil (PLX 80% Working Interest) – Expansion Opportunity to the South of Existing Oil Development

Point Loma has also internally identified and captured a Mannville pool target south of the Corporation’s analogous Paddle River Lower Mannville oil producing property. The target zone is thicker and has similar reservoir quality to the existing Paddle River oil development that is operated by Point Loma. This could result in 10 to 12 follow-up opportunities with success. This opportunity has pipeline connection to a deep cut gas facility in the area which could accelerate on-stream timing and future development.

Banff Oil Exposure (PLX 80% Working Interest) – Two High Impact Targets

Based on proprietary 3D seismic shot by the Corporation, Point Loma has internally identified two Banff oil targets in the West Cove area located to the east of Paddle River. As interpreted, these pools are analogous to developments in the offsetting Cherhill and St. Anne areas which have accumulations of up to 90 MMbbls of original oil in place. The Corporation is looking to utilize horizontal multi-stage completions to develop these pools upon success. The only previous horizontal wells drilled in the region utilized dated technology and were completed as open holes yet achieved initial production rates ranging from 200 to 800 barrels of oil per day. Point Loma anticipates that the application of current drilling and completion technology could significantly improve these results.

About Point Loma

Point Loma is a public oil and gas exploration and development company focused on conventional and unconventional oil and gas reservoirs in west-central Alberta. The Company controls over 150,000 net acres (230 net sections) and has a deep inventory of oil opportunities in the Mannville (Upper and Lower), Banff and Duvernay Shale formations. Point Loma’s business plan is to utilize its experience to drill, develop and acquire accretive assets with potential for horizontal multi-stage frac technology and exploit opportunities for secondary recovery. For more information, please visit Point Loma’s website at www.pointloma.ca or Point Loma’s profile on the System for Electronic Document Analysis and Retrieval website at www.sedar.com.

For further information, please contact:

Terry Meek
President and CEO
Telephone: (403) 705-5051 ext. 444
tmeek@pointloma.ca

Thomas Love
Interim CFO
Telephone: (403) 705-5051 ext. 443
tlove@pointloma.ca

A Note Regarding Forward-Looking Information

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including without limitation, statements pertaining to the anticipated timing of production from the Corporation’s Wizard Lake well and the anticipated increase in oil and ngl production weighting for the Corporation, the anticipated timing of completion of the drilling and tie-in of the two farm-out wells at Wizard Lake, the anticipated results of the two farm-out wells and operational activities related therewith, anticipated capital to be spent on the two proposed farm-out wells, potential future targets and opportunities. Statements relating to “reserves” are also deemed to forward-looking statements, as they involve the implied assessment based on certain estimates and assumptions, that the reserves can be profitably produced in the future.

The use of any of the words “will”, “expects”, “believe”, “plans”, “potential” and similar expressions are intended to identify forward-looking statements or information. Although Point Loma believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because Point Loma cannot give assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with the oil and gas industry in general such as operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve and resource estimates; the inability of Point Loma to bring additional production on stream or in the anticipated quantities disclosed herein; the uncertainty of estimates and projections relating to reserves, resources, production, costs and expenses; health, safety and environmental risks; commodity price and exchange rate fluctuations; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of acquisitions; failure to realize the anticipated benefits of acquisitions; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws, royalties and environmental regulations, actual production from the acquired assets may be greater or less than estimates. Management has included the above summary of assumptions and risks related to forward-looking information provided in this press release in order to provide security holders with a more complete perspective on Point Loma’s future operations and such information may not be appropriate for other purposes.

The forward-looking statements and information contained in this press release are made as of the date hereof and Point Loma does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Oil and Gas Information

“BOEs” may be misleading, particularly if used in isolation. A BOE conversion ratio of six thousand cubic feet of natural gas to one barrel of oil equivalent (6 Mcf: 1 bbl) is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. As the value ratio between natural gas and crude oil based on the current prices of natural gas and crude oil is significantly different from the energy equivalency of 6:1, utilizing a conversion on a 6:1 basis may be misleading as an indication of value.

SOURCE: Point Loma Resources Ltd.

ReleaseID: 547101

HACKENSACK, NJ / ACCESSWIRE / May 30, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions’ translational oncology tools throughout Europe.

Champions’ European customers can continue their unique and consultative interactions with the Champions business development and project leadership teams, along with the option of performing the pharmacology work locally. An operations solution in Europe reduces the intercontinental logistics involved with performing the work in the US. This agreement provides Champions greater access to prospective European clients who prefer a local presence.

Ronnie Morris, Chief Executive Offer of Champions Oncology said, “This partnership will enhance the experience of our European customers by providing them with local operational execution. The expansion of our pharmacology services throughout Europe is a multi-year strategic initiative of Champions, and this partnership is a pivotal next step in that plan. This partnership also opens the door to expansion of additional global services, including clinical flow cytometry.”

“It was important for us to find a partner that both fit the culture of Champions, and met our high-quality, operational standards”, said David DeOrnellis, Vice President and Head of Global Laboratory Operations at Champions Oncology. “We are confident that we found this in TransCure bioServices, and we are excited about the new growth potential throughout Europe.”

“A partnership with Champions Oncology is key to growing our international expansion and allow us to apply our hu-mouse expertise in the field of PDX and clinical flow cytometry in Europe for long term customers relationships”, said Patrick NEF, Chief Executive Officer and co-founder of TransCure bioServices.”

“In our quest to provide the most relevant data and services to our international clients, Patient Derived Xenografts (PDX) models are clearly becoming the gold standard” according to Sebastien Tabruyn, Chief Scientific Officer at TransCure bioServices. “Being able to combine the best of the PDX with our capability to reconstitute the full human immune system in mouse models is a major advance for drug development scientists targeting immuno-oncology like check point inhibitors, CAR-T cells and new anti-cancer combination therapies.”

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to improve the development and use of oncology drugs. The Company’s TumorGraft technology platform is based on the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions to pharmaceutical and biotechnology companies seeking personalized approaches to drug development to lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

About TransCure bioServices SAS

TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines. If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, please refer to www.tcbioservices.com.

CONTACT:

Champions Oncology, Inc.
201-808-8400

SOURCE: Champions Oncology, Inc.

ReleaseID: 547063

New Products for Customers Include Disney Parks and Resorts, Tokyo Disney and Universal Studios

PHILLIPSBURG, NJ / ACCESSWIRE / May 30, 2019 / Edison Nation, Inc. a full-service product development company, has launched a new product line exclusively for its theme park and entertainment customers, which include Disney Parks and Resorts, as well as Universal Studios, among others.

The newly announced product line includes all-new branded products, such as an Avatar Light Up Wood Sprite and Star Wars Baton and Shield Set, exclusively developed for Disney Parks and Resorts; a Monsters Inc. interactive flashlight for Tokyo Disney; and a Jimmy Fallon microphone for Universal Resorts.

“Our theme park and entertainment customers, which include Disney and Universal, look to Edison Nation as a leading partner to develop innovative new products,” said Chris Ferguson, Chief Executive Officer of Edison Nation. “Our long-standing relationship offers Edison Nation a niche, exclusive distribution channel with a regular flow of new product opportunities as new movies and theme park attractions are developed. We’ve consistently showcased our ability to service brands large and small, from individual inventors, to global powerhouse brands such as Disney.”

About Edison Nation, Inc.

Edison Nation, Inc. is a vertically integrated innovation aggregation and full-service product development and manufacturing company, offering innovation sourcing, design, sales, fulfillment and shipping services. Edison Nation’s model is to provide a risk mitigated platform that connects innovators with companies to bring new products to market. For more information, please visit www.edisonnation.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing the Company’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing the Company’s products in global markets, competition in the market for consumer products, any inability to raise capital to fund operations and service the Company’s debt. Additional information that could lead to material changes in the Company’s performance is contained in its filings with the SEC. The Company is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

Investor Relations:

Greg Falesnik
Managing Director
MZ North America
Direct: 949-385-6449
EDNT@mzgroup.us

SOURCE: Edison Nation, Inc.

ReleaseID: 547086

New preclinical data involving pregabalin are consistent with peer-reviewed data involving gabapentin previously published in The Journal of Pain

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need, today announced positive results of recent preclinical studies of the effects of AV-101, VistaGen’s oral NMDA receptor glycine site antagonist, compared to pregabalin (Lyrica®1) in the Chung ligation model of pain, an accepted gold standard preclinical model for chronic neuropathic pain caused by nerve damage.

These preclinical studies were conducted under contract in the laboratory of Tony L. Yaksh, Ph.D., Professor in Anesthesiology at the University of California San Diego School of Medicine. This work demonstrated that AV-101 had a significant dose-response with similar efficacy in a rat model of a mononeuropathy as compared to pregabalin (Lyrica), which was used as an active comparator. Similar positive results involving AV-101 in this preclinical model, but using gabapentin (Neurontin®2) as an active control, were previously peer-reviewed and published in The Journal of Pain3. Detailed results of these new studies will be presented at an upcoming scientific conference.

“In this new preclinical study examining AV-101’s analgesic and behavioral profile compared to pregabalin, AV-101 demonstrated robust analgesic effects, similar to pregabalin, but fewer side effects as measured in the rotarod assay,” reported H. Ralph Snodgrass, Ph.D., VistaGen’s Chief Scientific Officer. “This study provides further support of AV-101’s potential to treat debilitating neuropathic pain, without causing the burdensome side effects and safety concerns associated with the medications currently used by millions of Americans to treat neuropathic pain, such as drowsiness, dizziness and risk of abuse.”

The U.S. Food and Drug Administration has granted Fast Track designation for the development of AV-101 as a non-opioid treatment of neuropathic pain.

About Neuropathic Pain

Neuropathic pain (NP) affects approximately 33 million people in the United States (excluding patients with back pain).4 It is characterized by a steady burning “pins and needles” or “electric shock” sensation that results in abnormal neuronal function after nerve damage resulting from traumatic injuries, viral infections, certain medications, or metabolic conditions such as diabetes. Current treatments for neuropathic pain include antidepressants, anticonvulsants (such as gabapentin and pregabalin), and opioids, among others. However, current medications may offer inadequate efficacy, have limiting side effects, and be associated with abuse.

About AV-101

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA glutamate receptor modulators. The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with multiple CNS diseases and disorders, including chronic neuropathic pain, epilepsy, major depressive disorder, Parkinson’s disease levodopa-induced dyskinesia and many others. AV-101 is an oral prodrug of 7-Cl-KYNA which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new at-home treatment for multiple CNS indications with high unmet need. The FDA has granted Fast Track designation for development of AV-101 as both a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain.

About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other CNS diseases and disorders with high unmet need. VistaGen’s pipeline includes three CNS drug candidates, AV-101, PH10, and PH94B. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

1 Marketed by Pfizer in the U.S. as Lyrica®.

2 Marketed by Pfizer in the U.S. as Neurontin®.

3 Yaksh, T.L., et al. (2017). Characterization of the Effects of L-4-Chlorokynurenine on Nociception in Rodents. The Journal of Pain 18:1184-1196.

4 DiBonaventura, M.D., Sadosky, A., Concialdi, K., Hopps, M., Kudel, I., Parsons, B., et al. (2017). The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey. J Pain Res 10:2525-2538.

Forward-Looking Statements

This release contains various statements concerning VistaGen’s future expectations, plans and prospects, including without limitation, our expectations regarding development and commercialization of our drug candidates, including AV-101 for neuropathic pain, all of which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and may cause actual results to differ materially from those contemplated in these forward-looking statements. Among these risks is the possibility that (i) we may encounter unexpected adverse events in patients during our clinical development of any product candidate that cause us to discontinue further development, (ii) we may not be able to successfully demonstrate the safety and efficacy of our product candidates at each stage of clinical development, (iii) success in preclinical studies or in early-stage clinical trials may not be repeated or observed in ongoing or future studies, and ongoing or future preclinical and clinical results may not support further development of, or be sufficient to gain regulatory approval to market our drug candidates, including AV-101, (iv) decisions or actions of regulatory agencies may negatively affect the progress of, and our ability to proceed with, further clinical studies or to obtain marketing approval for our drug candidates, (v) we may not be able to obtain or maintain adequate intellectual property protection and other forms of marketing and data exclusivity for our product candidates, (vi) we may not have access to or be able to secure substantial additional capital to support our operations, including our ongoing clinical development activities, and (vii) we may encounter technical and other unexpected hurdles in the manufacturing and development of any of our product candidates. Certain other risks are more fully discussed in the section entitled “Risk Factors” in our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission (SEC). Our SEC filings are available on the SEC’s website at www.sec.gov. In addition, any forward-looking statements represent our views only as of the issuance of this release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Company Contact

Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact

Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Media Contact

Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com

SOURCE: VistaGen Therapeutics

ReleaseID: 547091

NEW YORK, NY / ACCESSWIRE / May 30, 2019 / OTC Markets Group Inc. (OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced KushCo Holdings, Inc. (OTCQX: KSHB) has qualified to trade on the OTCQX® Best Market. KushCo Holdings, Inc. upgraded to OTCQX from the OTCQB® Venture Market.

KushCo begins trading today on OTCQX under the symbol “KSHB.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“We’re excited to welcome KushCo Holdings, Inc. to our OTCQX Best Market,” said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. “Having traded on our OTCQB Venture Market since 2016, KushCo’s graduation to the OTCQX Best Market demonstrates how companies are using the OTC Market tiers to build visibility and long-term shareholder value in the U.S. public markets.”

KushCo’s Chief Executive Officer, Nick Kovacevich, commented, “We are very pleased with the announcement of our upgrade to OTCQX as it is expected to improve liquidity and broaden awareness of KushCo in the financial markets. Our upgrade to OTCQX is another mile marker signifying our remarkable progress over the past several years, including internal upgrades to support best practices in corporate governance and record-breaking revenues of $35.2 million in our most recent quarterly results, an increase of 240% compared with Q2 2018. We are now better positioned to attract institutional investors as we execute on our long-term growth plan to profitability.”

Northland Securities, Inc. acted as the company’s OTCQX sponsor.

About KushCo Holdings, Inc.

KushCo Holdings, Inc. (OTCQX: KSHB) (www.kushco.com) is the premier producer of ancillary products and services to the cannabis and hemp industries. KushCo Holdings’ subsidiaries and brands provide, product quality, exceptional customer service, compliance knowledge and a local presence in serving its diverse customer base.

Founded in 2010, KushCo Holdings has now sold more than 1 billion units to growers, processors and producers across North America, South America, and Europe.

The Company has been featured in media nationwide, including CNBC, Los Angeles Times, TheStreet.com, Entrepreneur, and business magazine Inc. While KushCo Holdings provides products and solutions to customers in the cannabis and CBD industries, it has no direct involvement with the cannabis plant or any products that contain THC or CBD.

For more information, visit www.kushco.com or call (888)-920-5874.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed

Forward-Looking Statements

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. These “forward-looking” statements include statements relating to, among other things, the expected revenue attributable to the supply arrangements and the Company’s expectation that the supply arrangements-in-principle will become binding on the parties upon execution of definitive documents. While these forward-looking statements represent the Company’s current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company’s management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: “potential,” “look forward,” “expect,” “believe,” “dedicated,” “building,” or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by the Company herein are often discussed in filings the Company makes with the United States Securities and Exchange Commission (SEC), available at: www.sec.gov, and on the Company’s website, at: www.kushco.com.

CONTACTS:

KushCo Media Contact:

Anne Donohoe / Nick Opich
KCSA Strategic Communications
212-896-1265 / 212-896-1206
adonohoe@kcsa.com / nopich@kcsa.com

Investor Contact:

Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
212-896-1233 / 212-896-1203
ir@kushco.com

Media Contact:

OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

SOURCE: KushCo Holdings, Inc.

ReleaseID: 547119

Plug-and-Play Vehicle Recognition Available for Mass Market

CHANTILLY, VA / ACCESSWIRE / May 30, 2019 / Rekor Systems, Inc. (NASDAQ: REKR) (“Rekor”), a leading provider of innovative vehicle recognition systems, announced today that it is accepting pre-orders for Rekor Edge™, its all-in-one camera and vehicle recognition solution designed to instantaneously read vehicle license plates, along with the vehicle’s make, model, color and body type. Existing OCR-based license plate reading (“LPR”) can cost as much as $30,000 and are difficult to install and maintain. With an MSRP of only $1,599 and an accuracy rate exceeding 99 percent, the Rekor Edge™ will be the most cost-effective vehicle recognition solution on the market, enabling broad adoption of the Company’s vehicle recognition solutions in industries such as parking operations, logistics, customer loyalty, law enforcement – or virtually any business or government agency.

Until now, vehicle recognition solutions required significant technical expertise in integrating cameras, processors, and software to capture, read, convert, act upon, and store license plate and vehicle information. Rekor Edge™ provides all of this in one easy-to-use device, enabling nearly any business operator, homeowner’s association representative, or security system provider to implement vehicle recognition solutions.

“With this groundbreaking new product, we are opening a channel to any commercial business or government agency that has been unable to afford LPR systems. With the introduction of Rekor Edge™, we take a giant step closer to bringing our industry-changing technology to the broader market,” said Rod Hillman, Chief Operating Officer of Rekor. “Gone are the days of complicated, inaccurate, capital-intensive hardware that is dedicated only for the purpose of LPR and is expensive to maintain. With Rekor Edge™, we’re democratizing vehicle recognition solutions by bringing a cost-efficient and user-friendly solution to potential markets, applicable in any vertical where an accurate reading of a license plate is needed.”

Rekor Edge™ operates any 1080p-15fps with wide dynamic range and IR night vision, capturing full motion surveillance video, plate reads, and vehicle characteristics in all weather conditions. With plate reads at an industry-leading 99 percent accuracy, driven by a continuously improving machine learning engine, Rekor Edge™ opens the door to numerous business segments for LPR use. The system comes preloaded with a 3-year subscription to the vehicle recognition software, including maintenance, updates and support.

“We are excited about bringing the Rekor Edge™ to market because it performs all the functions of a traditional LPR system, contained within a small footprint security camera,” said Scott Rutherford, Rekor’s Executive Vice President of Innovation. “We are developing a family of products around this concept, with two more all-in-one systems and a universal edge device that will enable connection to any IP camera. Release of these additional products will be later this year. We have seen other devices that claim to have similar capabilities, but none of them come with the same highly accurate vehicle recognition out of the box.”

To learn more about the Rekor Edge™ Vehicle Recognition System, please visit our website.

About Rekor Systems, Inc.

Rekor Systems, Inc., a Nasdaq-listed (REKR) Delaware company, is the parent of Maryland-based Rekor Recognition Systems, Inc. Our smarter, faster, cost-competitive solutions are disrupting major industries in over 60 countries across the globe, including security and surveillance, public safety, electronic toll collection, brand loyalty, parking operations, banking and insurance, logistics, and traffic management. We use the power of artificial intelligence to analyze video streams images and transform them into extract actionable information for our clients. Our machine learning enabled software can turn most IP cameras into highly accurate and affordable vehicle recognition devices. Rekor provides advanced vehicle recognition systems, powered by its innovative OpenALPR software, which dramatically improves the accuracy of license plate reads and can also identify the make, model and color of vehicles. Rekor’s solutions include mobile and fixed license plate readers, “Move Over” law enforcement, school bus stop-arm enforcement, and red light and speed enforcement, parking enforcement and citation management. Rekor’s solutions help to protect lives, increase brand loyalty, and manage complex supply chain logistics. Our systems can dramatically reduce the cost of collecting tolls on major highways or manage congestion in the bumper-to-bumper traffic of large cities, without the need to install expensive new infrastructure. We make what was once considered impossible, possible. To learn more please visit our website: https://rekorsystems.com.

Forward-Looking Statements

This press release includes statements concerning Rekor Systems, Inc. and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the impact of Rekor’s core suite of AI-powered technology and the size of the market for global ALPR systems. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” by the negative of these terms or by other similar expressions. You are cautioned that such statements are subject to many risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual circumstances, events or results may differ materially from those projected in the forward-looking statements, particularly as a result of various risks and other factors identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events, or otherwise.

Media Contact:

Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

Investor Contact:

Charles Degliomini
Rekor Systems, Inc.
ir@rekorsystems.com

SOURCE: Rekor Systems, Inc.

ReleaseID: 547051

MANITOWOC, WI / ACCESSWIRE / May 30, 2019 / Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of enterprise-grade LED lighting and energy project solutions, announced today that Mike Altschaefl, CEO and Bill Hull, CFO will present at the 9th Annual LD Micro Invitational Conference Wednesday, June 5th at 9:40am PT/12:40am ET. The presentation will be webcast live.

Live Webcast / Replay URL: https://tinyurl.com/y5tr8lfx

Contact Wade Hickok wade@ldmicro.com or visit www.ldmicro.com for more information on the conference.

Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

LD Micro is an independent information resource and investment community event platform dedicated to providing valuable tools for everyone in the small and microcap investment universe. In 2015, it launched the LD Micro Index (the LDMi), the first pure microcap index, to provide a useful benchmark and flow of information to support participants in the microcap sector.

LD Micro Events

LD Micro hosts several sold-out investor conferences and management access events each year that are recognized among the strongest microcap events each year. Events include the LD Micro Invitational (June 4-5, 2019) and the LD Micro Main Event (early December) both held in Los Angeles, as well as smaller, periodic Investor Summits (New York, San Francisco, etc.) as well as Virtual Conferences to round out microcap management access opportunities throughout the year.

About Orion Energy Systems

Orion is a provider of enterprise-grade LED lighting and energy project solutions. Orion manufactures and markets connected lighting systems encompassing LED solid-state lighting and smart controls. Orion systems incorporate patented design elements that deliver significant energy efficiency, optical and thermal performance that drive financial, environmental, and work-space benefits for a wide variety of customers, including nearly 40% of the Fortune 500.

Twitter: @OrionLighting and @OrionLightingIR
StockTwits: Orion_LED_IR

Investor Relations Contacts

Bill Hull, CFO
Orion Energy Systems, Inc.
(312) 660-3575

William Jones; Tanya Kamatu
Catalyst IR
(212) 924-9800 or oesx@catalyst-ir.com

SOURCE: Orion Energy Systems, Inc.

ReleaseID: 547038